Literature DB >> 32563170

Seizure with CSF lymphocytosis as a presenting feature of COVID-19 in an otherwise healthy young man.

Shane Lyons1, Brendan O'Kelly2, Sara Woods3, Colm Rowan4, Deirdre Brady5, Gerard Sheehan6, Shane Smyth7.   

Abstract

Entities:  

Keywords:  COVID-19; Epilepsy; Seizure

Mesh:

Year:  2020        PMID: 32563170      PMCID: PMC7278645          DOI: 10.1016/j.seizure.2020.06.010

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


× No keyword cloud information.
A 20-year old previously well man was brought to hospital following a seizure. For three days he had complained of myalgia, lethargy and fever. On attempting to get out of bed at home, he had experienced lightheadedness with blurred and double vision and felt his legs were too weak to allow him walk. He then had a generalised tonic-clonic seizure, which lasted one minute. In the wake of the seizure he was confused and aggressive, requiring intravenous midazolam in the emergency department. He was febrile (101.3 F) with heart rate 85bpm, respiratory rate 12, and sO2 97 % on room air. Respiratory examination was normal. His confusion resolved within six hours with no deficits and a normal neurological examination. He was isolated and treated with levetiracetam, aciclovir, ceftriaxone and vancomycin for possible central nervous system (CNS) infection. There was no prior history of seizures or epilepsy; psychomotor delay; head injury or CNS infection and no history of recent travel. A nasopharyngeal swab for severe acute respiratory syndrome conornavirus 2 (SARS-CoV-2) and influenza was negative and isolation precautions were discontinued. Routine blood tests were largely unremarkable (Table 1 ). Chest x-ray was normal. A CT brain and MRI brain were unremarkable, apart from mild mucosal thickening noted in the sphenoid sinus. CSF analysis demonstrated a lymphocytic pleocystosis (21 cells/mm3, 99 % mononuclear, 1% polymorphs) with normal protein and gluose (Table 1). CSF culture demonstrated no growth and PCR for herpes simplex virus, varicella zoster virus, and enterovirus was negative. Within two days of his admission, the patient’s wife developed respiratory symptoms and tested positive for SARS-CoV-2 at another hospital. The patient was isolated again and a repeat nasopharyngeal swab for SARS-CoV-2 was positive. CSF PCR for SARS-CoV-2 was negative. The patient remained well and was discharged home. EEG, performed on outpatient follow-up for infection control reasons, was normal.
Table 1

Clinical Laboratory Results.

VariableReference RangeValue
Haemoglobin (g/dL)13.0−18.016.2
Haematocrit (%)0.400−0.5000.455
White cell count (x109/LL)3.50−11.0012.02*
Neutrophils (x109/L)2.00−8.007.83
Lymphocytes (x109/L)1.00−4.003.07
Platelets (x109/L)150−400210
Sodium (mmol/liter)133−146138
Potassium (mmol/liter)3.3−5.03.8
Chloride (mmol/liter)95−108103
Carbon dioxide (mmol/liter)22−2925
Urea (mmol/liter)2.8−8.65.4
Creatinine (umol/liter)65−10781
C- reactive protein (mg/liter)<74
Glucose (mmol/L)3.7−6.05.7
D-dimer (mg/L)0.00−0.500.35
Ferritin (ug/l)22−275281*
Albumin (g/L)35−5045
Alanine transferase (iu/L)0−55356*
Alkaline Phosphatase (iu/L)30−13073
Anion gap (mmol/L)10−1610
CSF
Red cells022
White cells0−421
Protein (mg/L)150−450404
Glucose (mmol/L)3.2

The value in the patient was above the normal range.

Clinical Laboratory Results. The value in the patient was above the normal range. Neurological symptoms occuring in the context of COVID-19 are not uncommon, Mao et al. reported a rate of 36.4% (78/214). Neurological symptoms were more common among those who were systemically unwell (45.5 %, 40/88) and may be secondary to sepsis and organ dysfunction. [1] Coronaviruses have the potential to invade the CNS. Possible routes include haematogenous or lymphatic spread or neural invasion with retrograde transport. [2] A case of acute necrotising encephalitis related to COVID-19 has been reported [1,3]. Although CSF lymphocytosis may occur in unprovoked seizures, in this case the viral prodrome and identification of an infectious agent argues against this as a sole cause of pleocytosis [4]. Our case helps confirm that COVID-19 may involve the CNS, potentially causing a meningoencephalitis. In our patient the lack of obvious respiratory involvement, the overall mild clinical course, and the initial falsely negative nasopharyngeal swab testing were all noteworthy features.

Declaration of Competing Interest

None to declare.
  15 in total

Review 1.  COVID-19 associated brain/spinal cord lesions and leptomeningeal enhancement: A meta-analysis of the relationship to CSF SARS-CoV-2.

Authors:  Ariane Lewis; Rajan Jain; Jennifer Frontera; Dimitris G Placantonakis; Steven Galetta; Laura Balcer; Kara R Melmed
Journal:  J Neuroimaging       Date:  2021-06-08       Impact factor: 2.324

Review 2.  Cerebrospinal fluid in COVID-19: A systematic review of the literature.

Authors:  Ariane Lewis; Jennifer Frontera; Dimitris G Placantonakis; Jennifer Lighter; Steven Galetta; Laura Balcer; Kara R Melmed
Journal:  J Neurol Sci       Date:  2021-01-10       Impact factor: 3.181

Review 3.  Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19).

Authors:  Biyan Nathanael Harapan; Hyeon Joo Yoo
Journal:  J Neurol       Date:  2021-01-23       Impact factor: 4.849

Review 4.  Post-COVID 19 neurological syndrome: Implications for sequelae's treatment.

Authors:  William Camargo-Martínez; Ivan Lozada-Martínez; Angie Escobar-Collazos; Aura Navarro-Coronado; Luis Moscote-Salazar; Alfonso Pacheco-Hernández; Tariq Janjua; Pilar Bosque-Varela
Journal:  J Clin Neurosci       Date:  2021-04-08       Impact factor: 1.961

Review 5.  Neurological Complications of COVID-19: Underlying Mechanisms and Management.

Authors:  Ghaydaa A Shehata; Kevin C Lord; Michaela C Grudzinski; Mohamed Elsayed; Ramy Abdelnaby; Hatem A Elshabrawy
Journal:  Int J Mol Sci       Date:  2021-04-15       Impact factor: 5.923

Review 6.  Cerebrospinal fluid findings in patients with seizure in the setting of COVID-19: A review of the literature.

Authors:  Elizabeth Carroll; Kara R Melmed; Jennifer Frontera; Dimitris G Placantonakis; Steven Galetta; Laura Balcer; Ariane Lewis
Journal:  Seizure       Date:  2021-05-17       Impact factor: 3.414

7.  Acute new-onset symptomatic seizures in the context of mild COVID-19 infection.

Authors:  Maria Gaughan; Sean Connolly; Shamindra Direkze; Justin A Kinsella
Journal:  J Neurol       Date:  2020-09-10       Impact factor: 4.849

8.  COVID-19, de novo seizures, and epilepsy: a systematic review.

Authors:  Ali A Asadi-Pooya; Leila Simani; Mina Shahisavandi; Zohreh Barzegar
Journal:  Neurol Sci       Date:  2020-11-25       Impact factor: 3.830

Review 9.  COVID-19-Associated Neurological Disorders: The Potential Route of CNS Invasion and Blood-Brain Relevance.

Authors:  Aneesha Achar; Chaitali Ghosh
Journal:  Cells       Date:  2020-10-27       Impact factor: 6.600

Review 10.  Differential Diagnosis and Hospital Emergency Management for Fastlane Treatment of Central Nervous System Infection Under the COVID-19 Epidemic in Changsha, China.

Authors:  Haojun Yang; Yunfang Chi; Zhuohui Chen; Yishu Fan; Haiyue Wu; Xinhang Hu; Tong Wu; Bo Xiao; Mengqi Zhang
Journal:  Front Neurol       Date:  2020-10-20       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.